Healthy Skepticism Library item: 15844

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Bowie C.
Biologics set to dominate pharma sales
PharmaTimes 2009 Jun 19
http://www.pharmatimes.com/WorldNews/article.aspx?id=16075

Full text:

Seven of the top 10 and all of the top six drugs will be biologics in just five years time, says a new report from analysts at Evaluate Pharma. Heading the pack will be Roche’s cancer antibody Avastin (bevacizumab) – reeling in $9.2 billion in sales despite its recent setbacks for adjuvant use in colon cancer – but closely followed by Abbott and Eisai’s arthritis medication Humira (adalimumab) at $9.1 billion.

Roche’s cancer offering Rituxan (rituximab; $7.8 billion), Wyeth/Amgen/Takeda’s Enbrel for arthritis (etanercept; $6.5 billion), Sanofi-Aventis’ diabetes giant Lantus (insulin glargine; $6.4 billion), Roche’s Herceptin (trastuzumab; $5.8 billion) and Schering-Plough, J&J’s Remicade (infliximab; $5.2 billion) make up the other biologics expected to dominate the world pharmaceutical market in 2014.

The fact that a biotech product will assume Lipitor’s (atorvastatin) crown after Pfizer’s multi billion dollar cholesterol lowering drug goes off patent in 2012, indicates the increasing importance of biotech drugs – and specifically cancer antibodies, say the analysts.

Last year, four of the top-five were small molecule drugs, with Lipitor bringing in a phenomenal $13.5 billion. Avastin only just made it into the league table in tenth place.

However, while there is a clear shift towards biologics, Evaluate Pharma says small molecule drugs will still make up the bulk of pharma’s revenues, at $406 billion in 2014 compared to $169 billion for biotech products. “Nevertheless,” the report adds, “the weight of evidence for a shift to biotech products as the industry’s growth driver is overwhelming, making the recent moves by big pharma to access biotech platforms…all the more compelling.”